Drug derived from sea creature may help ovarian cancer patients


"Sifting through puddles from the firehose of last week’s American Society of Clinical Oncology annual meeting brought to my attention some promising news from the world of ovarian cancer," writes David Kroll.

"This early efficacy study with a synthetic drug based on a naturally-occurring molecule also demonstrates the continued value of prospecting the planet to harvest chemical diversity for the relief of human suffering."

Read David's analysis of the marine-derived drug for cancer, Yondelis® (trabectedin, ET-743), developed by Spain's PharmaMar SA and already approved for ovarian cancer patients in the European Union and Japan.